News|Videos|November 18, 2026

Making Liver Fibrosis Testing Routine, With Zobair Younossi, MD, MPH

Fact checked by: Sydney Jennings

Second-line noninvasive tests add the most value in adults 65 and older, but awareness gaps limit fibrosis risk stratification in primary care.

Most adults at risk for advanced liver fibrosis are still not being risk stratified, despite aligned guidance from liver, gastroenterology, endocrine, and obesity societies, according to Zobair M. Younossi, MD, MPH, who presented data on sequential noninvasive testing in primary care at The Liver Meeting 2026 in Denver, Colorado.

“The barrier right now is awareness,” Younossi, chairman of the Global NASH/MASH Council and professor and chairman of Beatty Liver and Obesity Research at Inova Health System in Falls Church, Virginia, told Patient Care Online.

Where Do Second-Line Tests Add the Most Value?

AASLD guidance recommends a second noninvasive test, such as vibration-controlled transient elastography (VCTE) or the Enhanced Liver Fibrosis (ELF) test, when the Fibrosis-4 index (FIB-4) is 1.3 or higher.1 In Younossi’s analysis, which modeled performance in a US primary care population, that second step was most valuable in adults aged 65 years and older.2 In this group, FIB-4 alone had a positive predictive value of 17% in participants with type 2 diabetes and 4% in those with medically complicated obesity. Adding VCTE raised the positive predictive value to 88% and 80%, respectively.2

What Would Improve Implementation?

Younossi outlines 3 steps to bring these algorithms into routine care. First, embedding FIB-4 and automatic second-line testing in the electronic health record could make risk stratification easier and flag only patients who need follow-up. Second, clinicians need evidence that risk stratification and treatment save lives and reduce costs. Third, he expects liver assessment to eventually become a quality metric in primary care, alongside eye and kidney checks for patients with diabetes.

“A patient who walks in with diabetes just doesn’t walk in with one disease,” he said.

Watch the full interview to hear Younossi discuss the care pathways primary care clinicians need and why liver health deserves more attention in metabolic disease management.

Editors’ Note: Younossi reports relevant disclosures with Intercept, Boehringer Ingelheim, Ipsen, BMS, GSK, Novo Nordisk, Madridgal, Merck, Aligos, Akero, Sanofi, and others.


The following transcript has been lightly edited using AI.

Patient Care Online: Where are we still missing the mark when it comes to implementing these tests in practice, and what needs to happen for these algorithms to be more widely adopted?

Younossi: I think we’re barely scratching the tip of the iceberg. The majority of patients are not risk stratified, and the guidelines are all there. There are guidelines from the liver and GI societies, and also from the endocrine and obesity societies. They have to be implemented, and implementing guidelines is difficult.

One thing that would help, in my view, is making this easy for our primary care physicians. How do we do that? You put it in the electronic health record. You make second-line testing automatically available, and you flag only the patients who are at risk and need to be linked to care.

Another thing that will help implementation is convincing our colleagues in primary care that risk stratification and treatment will actually save lives. Our poster being presented today looks at this 2-step risk stratification, FIB-4 followed by VCTE or FIB-4 followed by ELF, and shows that it will save lives, save quality-adjusted life-years, and save money in terms of the future burden of disease. That information needs to be communicated to our primary care physicians so they start doing this.

The third thing, which I think is going to come at some point, is that this will become a quality metric for our primary care colleagues. If you’re sending your patient for an eye check because that’s your quality metric, or a kidney check, then a liver check should be part of that too. A patient who walks in with diabetes doesn’t walk in with just one disease. They walk in with diabetes and a risk of cardiovascular disease, kidney disease, eye disease, but also liver disease. That liver piece needs to come to the front of our primary care colleagues’ attention, because the same patient with all these high-risk scores can develop serious liver disease, cirrhosis, or liver cancer, and we need to make sure they understand this.

So right now, the barrier is awareness. The barrier is that these are not yet strong quality metrics. And the barrier is the systems: the algorithms and care pathways that need to be in place to make it easy for our colleagues to take care of these patients.

References

  1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.0000000000000323
  2. Younossi Z, Paik J, de Avila L, et al. Sequential algorithms using FIB-4, followed by VCTE or ELF to detect advanced fibrosis: validation of risk stratification strategy in the United States (U.S.) primary care setting. Presented at: The Liver Meeting 2026; November 5-9, 2026; Denver, CO.

Related to this article